Johns Hopkins Medicine develops early-detection biomarker for ALS and FTD linked to TDP-43 protein.

Johns Hopkins Medicine leads the development of an early-detection biomarker for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), both of which affect critical nerve cells and cause progressive degeneration. The biomarker identifies a protein linked to the TDP-43 protein, which has corrupted function in ALS and FTD patients. This could potentially detect the diseases before symptoms appear.

March 18, 2024
4 Articles